KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Accumulated Depreciation & Amortization (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 10.97% to $11.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.4 million, a 10.97% increase, with the full-year FY2025 number at $11.4 million, up 10.97% from a year prior.
  • Accumulated Depreciation & Amortization was $11.4 million for Q4 2025 at Halozyme Therapeutics, up from $2.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $11.4 million in Q4 2025 to a low of $700000.0 in Q3 2021.
  • A 5-year average of $3.9 million and a median of $2.7 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 52.94% in 2021, then soared 234.19% in 2023.
  • Halozyme Therapeutics' Accumulated Depreciation & Amortization stood at $3.0 million in 2021, then skyrocketed by 116.65% to $6.5 million in 2022, then soared by 70.69% to $11.1 million in 2023, then decreased by 7.4% to $10.3 million in 2024, then grew by 10.97% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Accumulated Depreciation & Amortization are $11.4 million (Q4 2025), $2.7 million (Q3 2025), and $5.4 million (Q2 2025).